Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 8/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.55 |
| ▸ | ACVR1 | Q04771 | 4/20 | 0.49 |
| ▸ | AURKA | O14965 | 2/20 | 0.49 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.49 |
| ▸ | PAK4 | O96013 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | CSF1R | P07333 | 1/20 | 0.49 |
| ▸ | RET | P07949 | 1/20 | 0.49 |
| ▸ | IGF1R | P08069 | 1/20 | 0.49 |
| ▸ | MET | P08581 | 1/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5138780 | 0.74 | KDM4A (0.53) | PARP1SMN1; SMN2PDPK1CA12ALOX15 | |
| SCHEMBL2938806 | 0.73 | PARP1 (0.56) | PARP1SMN1; SMN2PDPK1CA12ALOX15 | |
| SCHEMBL5239248 | 0.72 | KDM4E (0.44) | PARP1AURKAABL1ALDH1A1HCAR2 | |
| Quinazolinone SCHEMBL27983253 | 0.71 | PARP1 (1.00) | PARP1SMN1; SMN2PDPK1CA12ALOX15 | |
| Quinazolinone SCHEMBL88525 | 0.71 | PARP1 (1.00) | PARP1SMN1; SMN2PDPK1CA12ALOX15 | |
| SCHEMBL259287 | 0.71 | KDM4E (0.63) | PARP1SMN1; SMN2PDPK1CA12ALOX15 | |
| SCHEMBL3759284 | 0.71 | HCAR2 (0.46) | PARP1AURKAALDH1A1HCAR2KDM4E | |
| SCHEMBL29371691 | 0.70 | — | — | |
| SCHEMBL11299370 | 0.70 | KDM4E (0.42) | PARP1AURKAABL1ALDH1A1HCAR2 | |
| SCHEMBL41738 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 187 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2408454-B1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP (CA) | 2024-07-24 | — | — | EP | claimed |
| CN-117136060-A | Methods of treating inflammatory diseases | 里邦医疗公司 | 2023-11-28 | — | — | CN | claimed |
| EP-3728207-B1 | QUINAZOLINONES AS PARP14 INHIBITORS | RIBON THERAPEUTICS INC (US) | 2023-02-01 | — | — | EP | claimed |
| CN-115427399-A | 2-heteroarylaminoquinazolinone derivatives | 住友制药株式会社 | 2022-12-02 | — | — | CN | claimed |
| CN-114984016-A | Compositions and methods for treating complement-associated diseases | 雷斯韦洛吉克斯公司 | 2022-09-02 | — | — | CN | claimed |
| EP-2785183-B1 | TRIAZOLOPYRIDINONE PDE10 INHIBITORS | MERCK SHARP & DOHME (US) | 2018-12-19 | — | — | EP | claimed |
| EP-3317277-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2018-05-09 | — | — | EP | claimed |
| WO-2017003723-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2017-01-05 | — | — | WO | claimed |
| US-20130203756-A1 | ISOINDOLINE PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-08-08 | — | — | US | claimed |
| US-7169926-B1 | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-30 | — | — | US | claimed |
| EP-1608317-A4 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2006-12-27 | — | — | EP | claimed |
| EP-1608317-A2 | DIPEPTIDYL PEPTIDASE INHIBITORS | Takeda San Diego, Inc. (US) | 2005-12-28 | — | — | EP | claimed |
| US-20050004117-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2005-01-06 | — | — | US | claimed |
| US-20040242568-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2004-12-02 | — | — | US | claimed |
| WO-2004087053-A9 | DIPEPTIDYL PEPTIDASE INHIBITORS | SYRRX INC (US) | 2004-11-11 | — | — | WO | claimed |
| WO-2004087053-A2 | DIPEPTIDYL PEPTIDASE INHIBITORS | SYRRX, INC. (US) | 2004-10-14 | — | — | WO | claimed |
| EP-0733633-A1 | Heterocyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-09-25 | — | — | EP | claimed |
| EP-0180834-B1 | 4-Alkoxypyrido[2,3-d]pyrimidine derivatives, process for their preparation and medicaments containing them | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1989-08-30 | — | — | EP | claimed |
| EP-0180833-B1 | 4-Oxo-pyrido-[2,3-d]pyrimidine derivatives, process for their preparation and medicaments containing them | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1989-07-19 | — | — | EP | claimed |
| US-20260124209-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2026-05-07 | — | — | US | disclosed |
| US-12594276-B2 | Inhibitors of human immunodeficiency virus replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2026-04-07 | — | — | US | disclosed |
| US-20250249005-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2025-08-07 | — | — | US | disclosed |
| WO-2025073792-A1 | WRN INHIBITORY COMPOUNDS | FORX THERAPEUTICS AG (CH) | 2025-04-10 | — | — | WO | disclosed |
| WO-2025048759-A1 | BENZIMIDAZOLE DERIVATIVES AS MPGES-1 INHIBITORS | ICOSYN THERAPEUTICS SAGLIK TEKNOLOJILERI ANONIM SIRKETI (TR) | 2025-03-06 | — | — | WO | disclosed |
| WO-2025015167-A2 | ERASTIN KETONE ANALOGS AND USES THEREOF | EXARTA THERAPEUTICS, INC. (US) | 2025-01-16 | — | — | WO | disclosed |
| US-12152051-B2 | Cyclic dinucleotide analogue, pharmaceutical composition thereof, and application | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2024-11-26 | — | — | US | disclosed |
| CN-114874209-B | Oxadiazole transient receptor potential channel inhibitors | 豪夫迈·罗氏有限公司 | 2024-08-06 | — | — | CN | disclosed |
| EP-3854799-B1 | CYCLIC DINUCLEOTIDE ANALOGUE, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION | SHANGHAI DE NOVO PHARMATECH CO LTD (CN) | 2024-07-17 | — | — | EP | disclosed |
| US-12018016-B2 | Aryl sulfonyl (hydroxy) piperidines as CCR6 inhibitors | AMGEN INC. (US) | 2024-06-25 | — | — | US | disclosed |
| WO-2024112287-A1 | BENZIMIDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BANOGLU ERDEN (TR) | 2024-05-30 | — | — | WO | disclosed |
| EP-3630759-B1 | COMPOUNDS USEFUL AS ION CHANNEL INHIBITORS FOR THE TREATMENT OF CANCER | CENTRE NAT RECH SCIENT (FR) | 2024-05-01 | — | — | EP | disclosed |
| US-11932638-B2 | Ion channel inhibitor compounds for cancer treatment | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFQUE (FR) | 2024-03-19 | — | — | US | disclosed |
| CN-117561258-A | Novel substituted tricyclic aza heterocycles as SOS1 inhibitors | 唯久生物技术(苏州)有限公司 | 2024-02-13 | — | — | CN | disclosed |
| CN-117136060-A | Methods of treating inflammatory diseases | 里邦医疗公司 | 2023-11-28 | — | — | CN | disclosed |
| US-20230355626-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2023-11-09 | — | — | US | disclosed |
| US-20230303561-A1 | PYRIMIDINONE DERIVATIVE, PREPARATION METHOD THEREOF AND USE THEREOF IN RESISTING MYCOBACTERIUM TUBERCULOSIS INFECTION | INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2023-09-28 | — | — | US | disclosed |
| CN-114081890-B | Application of pyrimidinone derivative in resisting tubercle bacillus infection | 中国医学科学院医药生物技术研究所 | 2023-06-02 | — | — | CN | disclosed |
| US-11655245-B2 | Oxadiazole transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-11655245-B2 | Oxadiazole transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| EP-4180429-A1 | PYRIMIDINONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF AGAINST MYCOBACTERIUM TUBERCULOSIS INFECTION | Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences (CN) | 2023-05-17 | — | — | EP | disclosed |
| US-20230133406-A1 | Aryl Sulfonyl (Hydroxy) Piperidines as CCR6 Inhibitors | CHEMOCENTRYX, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230139111-A1 | DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20230139111-A1 | DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20230125684-A1 | Aryl Sulfonyl Compounds as CCR6 Inhibitors | CHEMOCENTRYX, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230121700-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2023-04-20 | — | — | US | disclosed |
| WO-2023023532-A2 | ARYL SULFONYL (HYDROXY) PIPERIDINES AS CCR6 INHIBITORS | CHEMOCENTRYX, INC. (US) | 2023-02-23 | — | — | WO | disclosed |
| WO-2023023534-A2 | ARYL SULFONYL COMPOUNDS AS CCR6 INHIBITORS | CHEMOCENTRYX, INC. (US) | 2023-02-23 | — | — | WO | disclosed |
| US-20220389007-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2022-12-08 | — | — | US | disclosed |
| CN-115427399-A | 2-heteroarylaminoquinazolinone derivatives | 住友制药株式会社 | 2022-12-02 | — | — | CN | disclosed |
| CN-114984016-A | Compositions and methods for treating complement-associated diseases | 雷斯韦洛吉克斯公司 | 2022-09-02 | — | — | CN | disclosed |
| US-20220274927-A1 | MEMBRANE-ACTIVE ANTI-BACTERIAL COMPOUNDS AND USES THEREOF | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2022-09-01 | — | — | US | disclosed |
| CN-114874209-A | Oxadiazole transient receptor potential channel inhibitors | 豪夫迈·罗氏有限公司 | 2022-08-09 | — | — | CN | disclosed |
| WO-2022160931-A1 | PYRIDOPYRIMIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江海正药业股份有限公司 | 2022-08-04 | — | — | WO | disclosed |
| CN-110461838-B | Oxadiazole transient receptor potential channel inhibitors | 豪夫迈·罗氏有限公司 | 2022-05-06 | — | — | CN | disclosed |
| CN-110225911-B | Oxadiazolone transient receptor potential channel inhibitors | 豪夫迈·罗氏有限公司 | 2022-04-05 | — | — | CN | disclosed |
| CN-114206853-A | Targeted protein degradation of PARP14 for therapy | 里邦医疗公司 | 2022-03-18 | — | — | CN | disclosed |
| EP-3544979-B1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-08-04 | — | — | EP | disclosed |
| EP-3544979-B1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-08-04 | — | — | EP | disclosed |
| EP-3854799-A1 | CYCLIC DINUCLEOTIDE ANALOGUE, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION | Shanghai de Novo Pharmatech Co., Ltd. (CN) | 2021-07-28 | — | — | EP | disclosed |
| EP-3854799-A1 | CYCLIC DINUCLEOTIDE ANALOGUE, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION | Shanghai de Novo Pharmatech Co., Ltd. (CN) | 2021-07-28 | — | — | EP | disclosed |
| US-10913742-B2 | Oxadiazolones as transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| EP-3768260-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2021-01-27 | — | — | EP | disclosed |
| CN-111867585-A | Oxadiazole transient receptor potential channel inhibitors | 豪夫迈·罗氏有限公司 | 2020-10-30 | — | — | CN | disclosed |
| US-20200308161-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2020-10-01 | — | — | US | disclosed |
| US-10710994-B2 | Oxadiazole transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-10711004-B2 | Oxadiazole transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-10711004-B2 | Oxadiazole transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| WO-2020057546-A1 | CYCLIC DINUCLEOTIDE ANALOGUE, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION | 上海迪诺医药科技有限公司 | 2020-03-26 | — | — | WO | disclosed |
| EP-3544979-A1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | H. Hoffnabb-La Roche Ag (CH) | 2019-10-02 | — | — | EP | disclosed |
| WO-2019182925-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2019-09-26 | — | — | WO | disclosed |
| WO-2019182925-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2019-09-26 | — | — | WO | disclosed |
| US-20190284179-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2019-09-19 | — | — | US | disclosed |
| US-20190284189-A1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2019-09-19 | — | — | US | disclosed |
| EP-2785183-B1 | TRIAZOLOPYRIDINONE PDE10 INHIBITORS | MERCK SHARP & DOHME (US) | 2018-12-19 | — | — | EP | disclosed |
| WO-2018162607-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-09-13 | — | — | WO | disclosed |
| WO-2018096159-A1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-05-31 | — | — | WO | disclosed |
| WO-2018096159-A1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-05-31 | — | — | WO | disclosed |
| US-9957267-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20180022810-A1 | USE OF CXCR3 INHIBITORS FOR PROTECTING AGAINST FETAL WASTAGE | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2018-01-25 | — | — | US | disclosed |
| EP-3066099-B1 | PYRIDO[2,3-D]PYRIMIDIN-4-ONE COMPOUNDS AS TANKYRASE INHIBITORS | LILLY CO ELI (US) | 2017-09-06 | — | — | EP | disclosed |
| US-9630962-B2 | 4-amino-6-(2,6-dichlorophenyl)-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8H)-one derivatives, synthesis and uses thereof | HOSPITAL CLINIC DE BARCELONA (ES) | 2017-04-25 | — | — | US | disclosed |
| EP-3008063-B1 | 4-AMINO-6-(2,6-DICHLOROPHENYL)-2-(PHENYLAMINO)-PYRIDO(2,3-D)PYRIMIDIN-7(8H)-ONE DERIVATIVES, SYNTHESIS AND USES THEREOF | INST QUÍMIC DE SARRIÁ CETS FUNDACIÓ PRIVADA (ES) | 2017-04-19 | — | — | EP | disclosed |
| US-9624218-B2 | Pyrido[2,3-d]pyrimidin-4-one compounds as tankyrase inhibitors | ELI LILLY AND COMPANY (US) | 2017-04-18 | — | — | US | disclosed |
| US-9624218-B2 | Pyrido[2,3-d]pyrimidin-4-one compounds as tankyrase inhibitors | ELI LILLY AND COMPANY (US) | 2017-04-18 | — | — | US | disclosed |
| US-9624218-B2 | Pyrido[2,3-d]pyrimidin-4-one compounds as tankyrase inhibitors | ELI LILLY AND COMPANY (US) | 2017-04-18 | — | — | US | disclosed |
| US-9540371-B2 | Substituted quinazolin-4(3H)-ones, pyrido[3,4-d]pyrimidin-4(3H)-ones, pyrido[3,2-d]pyrimidin-4(3H)-ones and pyrido[2,3-d]pyrimidin-4(3H)-ones as positive allosteric modulators of muscarinic acetycholine receptor M1 | VANDERBILT UNIVERSITY (US) | 2017-01-10 | — | — | US | disclosed |
| US-20170002001-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2017-01-05 | — | — | US | disclosed |
| EP-3066099-A1 | PYRIDO[2,3-d]PYRIMIDIN-4-ONE COMPOUNDS AS TANKYRASE INHIBITORS | Eli Lilly and Company (US) | 2016-09-14 | — | — | EP | disclosed |
| EP-3066099-A1 | PYRIDO[2,3-d]PYRIMIDIN-4-ONE COMPOUNDS AS TANKYRASE INHIBITORS | Eli Lilly and Company (US) | 2016-09-14 | — | — | EP | disclosed |
| US-20160251348-A1 | PYRIDO[2,3-d]PYRIMIDIN-4-ONE COMPOUNDS AS TANKYRASE INHIBITORS | ELI LILLY AND COMPANY | 2016-09-01 | — | — | US | disclosed |
| US-20160251348-A1 | PYRIDO[2,3-d]PYRIMIDIN-4-ONE COMPOUNDS AS TANKYRASE INHIBITORS | ELI LILLY AND COMPANY | 2016-09-01 | — | — | US | disclosed |
| US-20160176866-A1 | 4-AMINO-6-(2,6-DICHLOROPHENYL)-2-(PHENYLAMINO)-PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONE DERIVATIVES, SYNTHESIS AND USES THEREOF | INSTITUT QUÍMIC DE SARRIÁ, CETS FUNDACIÓ, PRIVADA (ES) | 2016-06-23 | — | — | US | disclosed |
| US-20160159814-A1 | GLYCINE TRANSPORTER INHIBITOR | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2016-06-09 | — | — | US | disclosed |
| US-20160159814-A1 | GLYCINE TRANSPORTER INHIBITOR | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2016-06-09 | — | — | US | disclosed |
| EP-3026043-A1 | GLYCINE TRANSPORTER INHIBITOR | Taisho Pharmaceutical Co., Ltd. (JP) | 2016-06-01 | — | — | EP | disclosed |
| CN-105593227-A | Pyrido [2,3-d ] pyrimidin-4-one compounds as tankyrase inhibitors | LILLY CO ELI | 2016-05-18 | — | — | CN | disclosed |
| CN-105593227-A | Pyrido [2,3-d ] pyrimidin-4-one compounds as tankyrase inhibitors | LILLY CO ELI | 2016-05-18 | — | — | CN | disclosed |
| US-9266881-B2 | Triazolopyridinone PDE10 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-02-23 | — | — | US | disclosed |
| WO-2015155306-A1 | NEW TRPA1 ANTAGONISTS | ALMIRALL, S.A. (ES) | 2015-10-15 | — | — | WO | disclosed |
| WO-2015069512-A1 | PYRIDO[2,3-d]PYRIMIDIN-4-ONE COMPOUNDS AS TANKYRASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2015-05-14 | — | — | WO | disclosed |
| WO-2015069512-A1 | PYRIDO[2,3-d]PYRIMIDIN-4-ONE COMPOUNDS AS TANKYRASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2015-05-14 | — | — | WO | disclosed |
| EP-2813504-A1 | 4-Amino-6-(2,6-dichlorophenyl)-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8H)-one derivatives, synthesis and uses thereof | Institut Quimic De Sarriá Cets, Fundació Privada (ES) | 2014-12-17 | — | — | EP | disclosed |
| US-20140343053-A1 | TRIAZOLOPYRIDINONE PDE10 INHIBITORS | MERCK SHARPE & DOHME CORP. (US) | 2014-11-20 | — | — | US | disclosed |
| EP-2785183-A1 | TRIAZOLOPYRIDINONE PDE10 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2014-10-08 | — | — | EP | disclosed |
| WO-2014106800-A2 | SUBSTITUTED 2-AMINO PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2014-07-10 | — | — | WO | disclosed |
| WO-2014087165-A1 | TANKYRASE INHIBITORS | UNIVERSITY OF BATH (GB) | 2014-06-12 | — | — | WO | disclosed |
| US-20130281397-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | RVX THERAPEUTICS INC. (CA) | 2013-10-24 | — | — | US | disclosed |
| EP-2632461-A1 | ISOINDOLINONE PDE10 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-09-04 | — | — | EP | disclosed |
| US-20130203756-A1 | ISOINDOLINE PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-08-08 | — | — | US | disclosed |
| WO-2013074390-A1 | TRIAZOLOPYRIDINONE PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-05-23 | — | — | WO | disclosed |
| US-8399483-B2 | Quinoxaline and quinoline derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2013-03-19 | — | — | US | disclosed |
| WO-2012058133-A1 | ISOINDOLINONE PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-05-03 | — | — | WO | disclosed |
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| EP-2350029-A1 | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL COA DESATURASE INHIBITORS | Gilead Sciences, Inc. (US) | 2011-08-03 | — | — | EP | disclosed |
| US-20110105508-A1 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA, S.A. (BE) | 2011-05-05 | — | — | US | disclosed |
| US-7928106-B2 | 2-[2-(2,5-Difluoro-phenyl)-ethoxymethyl]-3H-pteridin-4-one; 2-2-(3-Fluoro-phenyl)-ethoxymethyl]-3H-pyrimido[4,5-d]pyrimidin-4-one; (5-Oxo-5,6-dihydro-pyrimido[4,5-c]pyridazin-7-ylmethyl)-carbamic acid benzyl ester, useful in treating diseases which are modulated by HM74A agonists e.g. dyslipidemia | HOFFMANN-LA ROCHE INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-7799795-B2 | Aryl nitrile compounds and compositions and their uses in treating inflammatory and related disorders | AMGEN INC. (US) | 2010-09-21 | — | — | US | disclosed |
| EP-1917250-B1 | ANTI-INFLAMMATORY ARYL NITRILE COMPOUNDS | AMGEN INC (US) | 2010-07-21 | — | — | EP | disclosed |
| EP-2029601-B1 | PYRIDOPYRIMIDINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-06-02 | — | — | EP | disclosed |
| WO-2010056230-A1 | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL COA DESATURASE INHIBITORS | CV THERAPEUTICS, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| EP-2178562-A1 | SYNERGISTIC COMBINATIONS OF VR-1 ANTAGONISTS AND COX-2 INHIBITORS | Novartis Ag (CH) | 2010-04-28 | — | — | EP | disclosed |
| US-7687625-B2 | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-30 | — | — | US | disclosed |
| US-7678909-B1 | 2-[2-(3-Amino-cyclohexyl)-5-benzyl-4-oxo-4,5-dihydro-imidazo[4,5-c]pyridin-3-ylmethyl]-benzonitrile; type 2 diabetes mellitus, diabetic dislipidemia, impaired glucose tolerance; female infertility, osteoporosis, male contraception and neurological disorders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-16 | — | — | US | disclosed |
| US-20100063032-A1 | SUBSTITUTED PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. | 2010-03-11 | — | — | US | disclosed |
| US-20100029697-A1 | SUBSTITUTED PYRIDO[3,2-E][1,2,4]TRIAZOLO[4,3-C]PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. | 2010-02-04 | — | — | US | disclosed |
| EP-2139895-A1 | AZA-PYRIDOPYRIMIDINONE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2010-01-06 | — | — | EP | disclosed |
| US-7632839-B2 | Mitotic kinesin inhibitors | MERCK & CO. INC. (US) | 2009-12-15 | — | — | US | disclosed |
| US-7632839-B2 | Mitotic kinesin inhibitors | MERCK & CO. INC. (US) | 2009-12-15 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-7572801-B2 | Pyridopyrimidinone derivatives which are HM74A agonists | HOFFMANN-LA ROCHE INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7550590-B2 | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-23 | — | — | US | disclosed |
| US-20090105283-A1 | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | GILEAD PALO ALTO, INC. | 2009-04-23 | — | — | US | disclosed |
| EP-2029601-A1 | PYRIDOPYRIMIDINONE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2009-03-04 | — | — | EP | disclosed |
| WO-2009010529-A1 | SYNERGISTIC COMBINATIONS OF VR-1 ANTAGONISTS AND COX-2 INHIBITORS | NOVARTIS AG (CH) | 2009-01-22 | — | — | WO | disclosed |
| US-7462623-B2 | Quinazoline derivatives as Src tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2008-12-09 | — | — | US | disclosed |
| EP-1985620-A1 | 10a-AZALIDE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2008-10-29 | — | — | EP | disclosed |
| US-20080255161-A1 | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | GILEAD PALO ALTO, INC. | 2008-10-16 | — | — | US | disclosed |
| WO-2008116742-A1 | AZA-PYRIDOPYRIMIDINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-02 | — | — | WO | disclosed |
| US-20080234277-A1 | NOVEL AZA-PYRIDOPYRIMIDINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-09-25 | — | — | US | disclosed |
| US-20080139586-A1 | Mitotic Kinesin Inhibitors | MERCK SHARP & DOHME CORP. | 2008-06-12 | — | — | US | disclosed |
| US-20080139586-A1 | Mitotic Kinesin Inhibitors | MERCK SHARP & DOHME CORP. | 2008-06-12 | — | — | US | disclosed |
| EP-1917250-A2 | ANTI-INFLAMMATORY ARYL NITRILE COMPOUNDS | Amgen, Inc (US) | 2008-05-07 | — | — | EP | disclosed |
| US-20070275987-A1 | Novel pyridopyprimidinone derivatives which are HM74A agonists | HOFFMAN-LA ROCHE INC | 2007-11-29 | — | — | US | disclosed |
| WO-2007134986-A1 | PYRIDOPYRIMIDINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-29 | — | — | WO | disclosed |
| US-20070060601-A1 | Mitotic kinesin inhibitors | MERCK SHARP & DOHME CORP. | 2007-03-15 | — | — | US | disclosed |
| US-20070060601-A1 | Mitotic kinesin inhibitors | MERCK SHARP & DOHME CORP. | 2007-03-15 | — | — | US | disclosed |
| US-7169926-B1 | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-30 | — | — | US | disclosed |
| US-20070015773-A1 | Aryl nitrile compounds and compositions and their uses in treating inflammatory and related disorders | AMGEN INC. | 2007-01-18 | — | — | US | disclosed |
| WO-2007002701-A2 | ANTI-INFLAMMATORY ARYL NITRILE COMPOUNDS | AMGEN INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060270849-A1 | Process for producing pyrimidin-4-one compound | UBE INDUSTRIES, LTD. (JP) | 2006-11-30 | — | — | US | disclosed |
| EP-1637523-A1 | PROCESS FOR PRODUCING PYRIMIDIN-4-ONE COMPOUND | Ube Industries, Ltd. (JP) | 2006-03-22 | — | — | EP | disclosed |
| US-20050004117-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2005-01-06 | — | — | US | disclosed |
| US-20040259870-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2004-12-23 | — | — | US | disclosed |
| US-20040242568-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2004-12-02 | — | — | US | disclosed |
| US-20040242566-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2004-12-02 | — | — | US | disclosed |
| US-20040122223-A1 | Non-natural nucleotides and dinucleotides | CELLTECH R & D LIMITED (GB) | 2004-06-24 | — | — | US | disclosed |
| US-6713484-B2 | FUSED RING PYRIMIDINE DERIVATIVES; LOW CYTOTOXICITY | WARNER-LAMBERT COMPANY | 2004-03-30 | — | — | US | disclosed |
| US-20030186987-A1 | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family | BRIDGES ALEXANDER JAMES (US) | 2003-10-02 | — | — | US | disclosed |
| EP-0733633-B1 | Heterocyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-05-28 | — | — | EP | disclosed |
| US-6521620-B1 | Suppressing tumors, especially breast cancers; antiproli-ferative agents; arthritis, vascular restenosis, psoriasis and angiogenesis; extremely low cytotoxicity | WARNER-LAMBERT COMPANY | 2003-02-18 | — | — | US | disclosed |
| US-6455534-B2 | ANTIPROLIVERATIVE, -CARCINOGENIC AND -TUMOR AGENTS; MITOGENESIS-ACTIVATED PROTEIN KINASE INHIBITORS; NONCYTOTOXIC; BINDING WITH HIGH AFFINITY AT THE ADENOSINE TRIPHOSPHATE BINDING SITE OF THE KINASES | WARNER-LAMBERT COMPANY | 2002-09-24 | — | — | US | disclosed |
| US-20010027197-A1 | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family | BRIDGES ALEXANDER JAMES (US) | 2001-10-04 | — | — | US | disclosed |
| US-6265410-B1 | ANTICARCINOGENIC AGENTS | WARNER-LAMBERT COMPANY | 2001-07-24 | — | — | US | disclosed |
| EP-0802914-B1 | ARYL- AND HETEROARYL- PURINE AND PYRIDOPYRIMIDINE DERIVATIVES | PHARMACIA & UPJOHN SPA (IT) | 2001-06-06 | — | — | EP | disclosed |
| US-6084095-A | INCLUDING 6-AMINO-4-(3-BROMOANILINO)PYRIDO(3,2-D)PYRIMIDINE; 4-(3-BROMOANILINO)-6-METHYLAMINOPYRIDO (3,2-D)PYRIMIDINE; AND 4-(3-BROMOANILINO)-6-METHYLAMINOPYRIDO(3,2-D)PYRIMIDINE; USEFUL IN TREATING PROLIFERATIVE DISEASES SUCH AS CANCER | WARNER-LAMBERT COMPANY (US) | 2000-07-04 | — | — | US | disclosed |
| US-5965563-A | NOVEL PURINE DERIVATIVES SUCH AS N6-(2-OXINDOL-5-YL) ADENINE, METHODS OF SYNTHESIZING THEM; USE AS TYROSINE KINASE INHIBITORS | PHARMACIA & UPJOHN S.P.A. (IT) | 1999-10-12 | — | — | US | disclosed |
| US-5654307-A | ANTICARCINOGENIC AGENTS, ANTIARTHRITIC AGENT, SKIN DISORDERS | WARNER-LAMBERT COMPANY (US) | 1997-08-05 | — | — | US | disclosed |
| EP-0742717-A1 | BICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY | WARNER-LAMBERT COMPANY (US) | 1996-11-20 | — | — | EP | disclosed |
| EP-0733633-A1 | Heterocyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-09-25 | — | — | EP | disclosed |
| WO-1995019774-A1 | BICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY | WARNER-LAMBERT COMPANY (US) | 1995-07-27 | — | — | WO | disclosed |
| US-5350749-A | Fungicides, insecticides and miticides | DOWELANCO (US) | 1994-09-27 | — | — | US | disclosed |
| US-5034393-A | Fungicides for plants | DOWELANCO (US) | 1991-07-23 | — | — | US | disclosed |
| US-5025011-A | Calcium-antigonist and beta-blocking properties; antihypertensives; vasodilators | SIMES, SOCIETA ITALIANA MEDICINALI E SINTETICI S.P.A. (IT) | 1991-06-18 | — | — | US | disclosed |
| EP-0414386-A1 | Condensed pyrimidine derivates | DowElanco (US) | 1991-02-27 | — | — | EP | disclosed |
| EP-0362908-A2 | 1,4-Dihydropyridine dicarboxylic acid derivatives | ZAMBON GROUP S.p.A. (IT) | 1990-04-11 | — | — | EP | disclosed |
| EP-0180834-B1 | 4-Alkoxypyrido[2,3-d]pyrimidine derivatives, process for their preparation and medicaments containing them | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1989-08-30 | — | — | EP | disclosed |
| EP-0180834-B1 | 4-Alkoxypyrido[2,3-d]pyrimidine derivatives, process for their preparation and medicaments containing them | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1989-08-30 | — | — | EP | disclosed |
| EP-0180833-B1 | 4-Oxo-pyrido-[2,3-d]pyrimidine derivatives, process for their preparation and medicaments containing them | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1989-07-19 | — | — | EP | disclosed |
| US-4762837-A | CARDIOVASCULAR DISORDERS | GODECKE AKTIENGESELLSCHAFT (DE) | 1988-08-09 | — | — | US | disclosed |
| CN-85107634-B | process for producing 4-oxo-pyrido (2,3-d) pyrimidine derivative | 歌德克股份公司 | 1988-07-06 | — | — | CN | disclosed |
| US-4681882-A | TREATMENT OF VASCULAR DISEASES | GODECKE AKTIENGESELLSCHAFT (DE) | 1987-07-21 | — | — | US | disclosed |
| US-4677108-A | CARDIOVASCULAR DISEASES | WARNER-LAMBERT COMPANY (US) | 1987-06-30 | — | — | US | disclosed |
| US-4677108-A | CARDIOVASCULAR DISEASES | WARNER-LAMBERT COMPANY (US) | 1987-06-30 | — | — | US | disclosed |
| EP-0180833-A1 | 4-Oxo-pyrido-[2,3-d]pyrimidine derivatives, process for their preparation and medicaments containing them | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1986-05-14 | — | — | EP | disclosed |
| EP-0180834-A1 | 4-Alkoxypyrido[2,3-d]pyrimidine derivatives, process for their preparation and medicaments containing them | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1986-05-14 | — | — | EP | disclosed |
| US-3962264-A | AMMONIA, TETRA-ALKOXY-PROPANE, MALONONITRILE | PFIZER INC. (US) | 1976-06-08 | — | — | US | disclosed |
| US-3950160-A | INHIBITING THE GROWTH OF WEEDS WITH 2-SUBSTITUTED PYRDIDOPYIMIDINES AND SALTS THEREOF | PFIZER INC. (US) | 1976-04-13 | — | — | US | disclosed |
| US-3950160-A | INHIBITING THE GROWTH OF WEEDS WITH 2-SUBSTITUTED PYRDIDOPYIMIDINES AND SALTS THEREOF | PFIZER INC. (US) | 1976-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (47 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133406-A1 | Aryl Sulfonyl (Hydroxy) Piperidines as CCR6 Inhibitors | CCR6, CCR1, CCR4 | PARP1 3626/4885SMN1; SMN2 482/4885PDPK1 3225/4885 |
| US-20050004117-A1 | Dipeptidyl peptidase inhibitors | DPP9, DPP4, DPP3 | PARP1 3791/4885SMN1; SMN2 3765/4885PDPK1 3110/4885 |
| US-12018016-B2 | Aryl sulfonyl (hydroxy) piperidines as CCR6 inhibitors | CCR6, CCR1, CCR4 | PARP1 3626/4885SMN1; SMN2 482/4885PDPK1 3225/4885 |
| US-20220389007-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, POLR2E, POLR2H | PARP1 772/4885SMN1; SMN2 2896/4885PDPK1 2662/4885 |
| US-20100029697-A1 | SUBSTITUTED PYRIDO[3,2-E][1,2,4]TRIAZOLO[4,3-C]PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS | CNR1, CNR2, FAAH | PARP1 67/4885SMN1; SMN2 461/4885PDPK1 561/4885 |
| US-20230303561-A1 | PYRIMIDINONE DERIVATIVE, PREPARATION METHOD THEREOF AND USE THEREOF IN RESISTING MYCOBACTERIUM TUBERCULOSIS INFECTION | DHPS, DHFR, QDPR | PARP1 1715/4885SMN1; SMN2 4552/4885PDPK1 971/4885 |
| US-20230139111-A1 | DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | RIPK1, RIPK4, RIPK3 | PARP1 1016/4885SMN1; SMN2 3951/4885PDPK1 22/4885 |
| US-12594276-B2 | Inhibitors of human immunodeficiency virus replication | SAMHD1, IRF3, SLC34A1 | PARP1 1850/4885SMN1; SMN2 1520/4885PDPK1 1992/4885 |
| US-20160176866-A1 | 4-AMINO-6-(2,6-DICHLOROPHENYL)-2-(PHENYLAMINO)-PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONE DERIVATIVES, SYNTHESIS AND USES THEREOF | BCL6, BCL9, BCL3 | PARP1 160/4885SMN1; SMN2 4003/4885PDPK1 165/4885 |
| US-20140343053-A1 | TRIAZOLOPYRIDINONE PDE10 INHIBITORS | PDE12, PDE10A, PDE5A | PARP1 857/4885SMN1; SMN2 2591/4885PDPK1 130/4885 |
| US-20010027197-A1 | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family | EGFR, ERBB2, ERBB3 | PARP1 4178/4885SMN1; SMN2 4072/4885PDPK1 1094/4885 |
| US-20130281397-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | BRD4, BMI1, BRPF3 | PARP1 280/4885SMN1; SMN2 2322/4885PDPK1 1145/4885 |
| US-10711004-B2 | Oxadiazole transient receptor potential channel inhibitors | TRPA1, TRPV1, TRPV3 | PARP1 4192/4885SMN1; SMN2 1022/4885PDPK1 1229/4885 |
| US-20040242566-A1 | Dipeptidyl peptidase inhibitors | DPP9, DPP3, DPP4 | PARP1 2025/4885SMN1; SMN2 4527/4885PDPK1 3101/4885 |
| US-10913742-B2 | Oxadiazolones as transient receptor potential channel inhibitors | TRPA1, TRPV1, TRPV3 | PARP1 4175/4885SMN1; SMN2 1207/4885PDPK1 1176/4885 |
| US-20170002001-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | SSTR5, SSTR2, SSTR4 | PARP1 4610/4885SMN1; SMN2 1197/4885PDPK1 1246/4885 |
| US-11655245-B2 | Oxadiazole transient receptor potential channel inhibitors | TRPA1, TRPV1, P2RX3 | PARP1 3336/4885SMN1; SMN2 1218/4885PDPK1 2726/4885 |
| US-20100063032-A1 | SUBSTITUTED PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS | CNR1, CNR2, FAAH | PARP1 75/4885SMN1; SMN2 448/4885PDPK1 829/4885 |
| US-20190284189-A1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | TRPA1, TRPV1, TRPV3 | PARP1 4175/4885SMN1; SMN2 1207/4885PDPK1 1176/4885 |
| US-11932638-B2 | Ion channel inhibitor compounds for cancer treatment | CACNA1E, KCNA1, KCNT1 | PARP1 675/4885SMN1; SMN2 3797/4885PDPK1 2039/4885 |
| US-20070275987-A1 | Novel pyridopyprimidinone derivatives which are HM74A agonists | GPR119, HCAR1, GPR84 | PARP1 1107/4885SMN1; SMN2 2757/4885PDPK1 1462/4885 |
| US-20040242568-A1 | Dipeptidyl peptidase inhibitors | DPP9, DPP4, DPP3 | PARP1 1840/4885SMN1; SMN2 4426/4885PDPK1 2094/4885 |
| US-12152051-B2 | Cyclic dinucleotide analogue, pharmaceutical composition thereof, and application | STING1, CGAS, IRF3 | PARP1 636/4885SMN1; SMN2 3571/4885PDPK1 1001/4885 |
| US-20220274927-A1 | MEMBRANE-ACTIVE ANTI-BACTERIAL COMPOUNDS AND USES THEREOF | LPO, EPCAM, ANTXR2 | PARP1 2903/4885SMN1; SMN2 1999/4885PDPK1 2152/4885 |
| US-20080234277-A1 | NOVEL AZA-PYRIDOPYRIMIDINONE DERIVATIVES | CHRM1, CHRM2, CHRM4 | PARP1 1443/4885SMN1; SMN2 1977/4885PDPK1 2204/4885 |
| US-20040259870-A1 | Dipeptidyl peptidase inhibitors | DPP9, DPP4, DPP3 | PARP1 1828/4885SMN1; SMN2 4500/4885PDPK1 2001/4885 |
| US-20060270849-A1 | Process for producing pyrimidin-4-one compound | DDC, ODC1, APRT | PARP1 445/4885SMN1; SMN2 2954/4885PDPK1 741/4885 |
| US-20190284179-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | TRPA1, TRPV1, TRPV3 | PARP1 3390/4885SMN1; SMN2 1161/4885PDPK1 2393/4885 |
| US-20040122223-A1 | Non-natural nucleotides and dinucleotides | P2RY1, P2RY11, P2RY13 | PARP1 543/4885SMN1; SMN2 2358/4885PDPK1 2169/4885 |
| US-20160159814-A1 | GLYCINE TRANSPORTER INHIBITOR | SLC1A2, SLC6A5, SLC18A2 | PARP1 4168/4885SMN1; SMN2 2637/4885PDPK1 2192/4885 |
| US-20260124209-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | ZC3HAV1, GTF3C1, ODC1 | PARP1 1887/4885SMN1; SMN2 2760/4885PDPK1 2927/4885 |
| US-20230125684-A1 | Aryl Sulfonyl Compounds as CCR6 Inhibitors | CCR6, CCR1, CCR3 | PARP1 4537/4885SMN1; SMN2 456/4885PDPK1 3065/4885 |
| US-20200308161-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | TRPA1, TRPV1, P2RX3 | PARP1 3336/4885SMN1; SMN2 1218/4885PDPK1 2726/4885 |
| US-20130203756-A1 | ISOINDOLINE PDE10 INHIBITORS | PDE12, PDE10A, PDE4A | PARP1 1929/4885SMN1; SMN2 2034/4885PDPK1 305/4885 |
| US-20230355626-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, POLR2E, POLR2H | PARP1 772/4885SMN1; SMN2 2896/4885PDPK1 2662/4885 |
| US-20160251348-A1 | PYRIDO[2,3-d]PYRIMIDIN-4-ONE COMPOUNDS AS TANKYRASE INHIBITORS | TNKS, TYMP, TNKS1BP1 | PARP1 162/4885SMN1; SMN2 1511/4885PDPK1 473/4885 |
| US-20070060601-A1 | Mitotic kinesin inhibitors | KIF5B, KIF2C, KIF18B | PARP1 1043/4885SMN1; SMN2 1973/4885PDPK1 219/4885 |
| US-10710994-B2 | Oxadiazole transient receptor potential channel inhibitors | TRPA1, TRPV1, TRPV3 | PARP1 3390/4885SMN1; SMN2 1161/4885PDPK1 2393/4885 |
| US-20230121700-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | TRPA1, TRPV1, TRPV3 | PARP1 3390/4885SMN1; SMN2 1161/4885PDPK1 2393/4885 |
| US-20070015773-A1 | Aryl nitrile compounds and compositions and their uses in treating inflammatory and related disorders | CCR1, MSR1, CCR2 | PARP1 3829/4885SMN1; SMN2 3305/4885PDPK1 2777/4885 |
| US-20080255161-A1 | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | SCD, SCD5, ECHS1 | PARP1 1729/4885SMN1; SMN2 3593/4885PDPK1 133/4885 |
| US-20090105283-A1 | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | SCD, SCD5, ECHS1 | PARP1 1729/4885SMN1; SMN2 3593/4885PDPK1 133/4885 |
| US-20110105508-A1 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | PDXK, PDPK1, PIKFYVE | PARP1 526/4885SMN1; SMN2 3405/4885PDPK1 2/4885 |
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | PARP1 4264/4885SMN1; SMN2 3120/4885PDPK1 4619/4885 |
| US-20080139586-A1 | Mitotic Kinesin Inhibitors | KIF5B, KIF2C, KIFC1 | PARP1 853/4885SMN1; SMN2 2063/4885PDPK1 206/4885 |
| US-20030186987-A1 | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family | EGFR, ERBB2, ERBB3 | PARP1 4267/4885SMN1; SMN2 3159/4885PDPK1 2101/4885 |
| US-20250249005-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, REV1, RTF2 | PARP1 644/4885SMN1; SMN2 2415/4885PDPK1 2954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.